Contact
searchSearch
HMP Global

Popular Now

Brain region graphic
News
TMS Shows Promise in Effective Obsessive-Compulsive Disorder Treatment
08/11/2023
Meagan Thistle
A recent systematic review and meta-analysis published in the journal Life reveals promising results for using Transcranial Magnetic Stimulation (TMS) in treating obsessive-compulsive disorder (OCD).
A recent systematic review and meta-analysis published in the journal Life reveals promising results for using Transcranial Magnetic Stimulation (TMS) in treating obsessive-compulsive disorder (OCD).
A recent systematic review and...
08/11/2023
Psych Congress Network
ehr buyers guide
White Papers
2024 EHR Buyer’s Guide for Executives
12/01/2023
This vendor agnostic EHR guide is based on objective research and opinions from industry experts.
This vendor agnostic EHR guide is based on objective research and opinions from industry experts.
This vendor agnostic EHR guide...
12/01/2023
Psychiatry & Behavioral Health
News
FDA Clears New Buprenorphine Option to Treat OUD
05/24/2023
Tom Valentino
One day after approving a new opioid overdose reversal nasal spray product, the US Food and Drug Administration approved Brixadi, a subcutaneous buprenorphine treatment option available in weekly and monthly formulations.
One day after approving a new opioid overdose reversal nasal spray product, the US Food and Drug Administration approved Brixadi, a subcutaneous buprenorphine treatment option available in weekly and monthly formulations.
One day after approving a new...
05/24/2023
Addiction Professional
Certification
Stay Up-to-Date With MATE
10/10/2023
Amanda Balbi
Have you heard? There are updated DEA requirements. The Medication Access and Training Expansion (MATE) Act requires prescribers renewing their DEA registration as of June 27, 2023, to have completed at least 8 hours of training on...
Have you heard? There are updated DEA requirements. The Medication Access and Training Expansion (MATE) Act requires prescribers renewing their DEA registration as of June 27, 2023, to have completed at least 8 hours of training on...
Have you heard? There are...
10/10/2023
Psychiatry & Behavioral Health
FDA
News
FDA Preliminary Evaluation Finds No Clear Link Between GLP-1 Drugs and Suicidal Thoughts, Cautions on Small Risk
01/26/2024
Meagan Thistle
The FDA's preliminary evaluation of GLP-1 RAs found no evidence that the medications cause suicidal drugs or actions but cautions that a small risk cannot yet be ruled out.
The FDA's preliminary evaluation of GLP-1 RAs found no evidence that the medications cause suicidal drugs or actions but cautions that a small risk cannot yet be ruled out.
The FDA's preliminary evaluation...
01/26/2024
Psych Congress Network

Sign Up

Psychiatry & Behavioral Health Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use